Here's more market data from PharmaGossip via Mathew Herper's blog that shows how the market for the top selling drugs has dramatically changed over the past two decades. Now, only 1 of the top 15 most-prescribed medicines is still sold only in it's branded version. New drug approvals peaked way back in the mid-90's and recent years are less than 50% of that peak performance.
All new, big-selling drugs now really tend to be biopharmaceutical products with high per patient treatment costs. Nine drugs now cost more than $200,000 per patient on an annual basis. Generics are here to stay. Broad-based blockbusters appear to be gone. New treatments will be targeted, more personalized, and more costly per patient -- but will presumably offer more specific patient benefits.
Posted by Bruce Lehr April 14th 2011.
Comments